Testing & Approvals
Swasti Veda is committed to continuous investment in the research and validation of our products. CoActiHerb has a Ministry of AYUSH, Haryana, manufacturing license and has been rigorously tested for safety and efficacy, and more tests are being conducted.
Safety
Each batch of CoActiHerb clears testing at NABL accredited laboratories to be declared safe for human consumption
- Toxicology: declared non-toxic for human consumption
- Heavy metals: including arsenic, cadmium, lead and mercury
- Pesticides: 35 varieties including chlorpyrifos and hexachlorocyclohexane
- Microbial contamination: yeast, mould, bacteria
Efficacy
Unaffiliated Open Study
CoActiHerb has been put through open studies conducted on 23 mildly and moderately affected COVID-19 patients. They received CoActiHerb along with standard treatment, and the formulation showed a positive correlation to improvement in IL-6, D-Dimer (quantitative), WBC count, differential leukocyte count, mean corpuscular haemoglobin concentration and platelet count parameters in several patients.
The patients reported qualitative improvements in blood oxygenation and symptoms of fatigue within a few days.
Quality Control
Each batch undergoes a qualitative analysis of phytochemical fingerprint profile matching, using ICP-MS, GCMSMS & LCMSQTOF, to reduce batch to batch variations and ensure product standardization.
Further Studies
- Clinical studies: Phase III and IV clinical studies for the use of CoActiHerb as a supplement or nutraceutical for Long COVID patients.
- Gene expression studies: A pioneer study for botanical medicine, using transcriptome (mRNA) sequencing to study the differential expression of genes in the immune cells of patients diagnosed with Long COVID and treated with CoActiHerb, to determine its specific mechanism of action.
- Batch ingredient analysis and batch manufacturing studies: Ensure high quality and homogeneity of ingredients, as well as uniform efficacy and potency of every batch manufactured.
